Park Place Capital Corp Has $348,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Park Place Capital Corp cut its position in Pfizer Inc. (NYSE:PFE) by 15.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,018 shares of the biopharmaceutical company’s stock after selling 2,201 shares during the quarter. Park Place Capital Corp’s holdings in Pfizer were worth $348,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PFE. LGT Group Foundation increased its holdings in Pfizer by 2.5% in the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares in the last quarter. ORG Partners LLC boosted its position in Pfizer by 1,729.9% in the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares during the last quarter. Kempner Capital Management Inc. bought a new stake in shares of Pfizer in the first quarter valued at $2,439,000. Leo Wealth LLC bought a new stake in shares of Pfizer in the fourth quarter valued at $2,171,000. Finally, Power Corp of Canada raised its stake in shares of Pfizer by 28.1% in the fourth quarter. Power Corp of Canada now owns 174,201 shares of the biopharmaceutical company’s stock valued at $5,015,000 after buying an additional 38,243 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.1 %

Shares of NYSE PFE opened at $29.18 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $165.35 billion, a PE ratio of -486.33, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67. The stock’s fifty day simple moving average is $29.14 and its two-hundred day simple moving average is $28.33. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $33.92.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.67 EPS. As a group, analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on PFE. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Barclays increased their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.